Research
Hormonal
GLP-1 receptor agonists reduce body weight primarily through central actions that induce satiety, rather than by increasing energy expenditure.
GLP-1 medications help you lose weight by making you feel full, not by boosting your metabolism. New oral versions exist, so you don't necessarily need injections.
StrongSupportsVERY_HIGH confidence
They also reduce body weight by inducing satiety through central actions.
Why this rating
Supported by multiple clinical trials and FDA/EMA approvals mentioned in the text.
Source
Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy
Matthias H. Tschöp et al. · Diabetologia · 2023
DOI 10.1007/s00125-023-05929-0
narrative_reviewCited 80×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →